Chinese Medicine: Subsidiary Receives Drug Registration Certificate for Injectable Isavuconazole Sulfate

The Chinese pharmaceutical company announced that its wholly-owned subsidiary, Sanyo Pharmaceuticals, has received the "Drug Registration Certificate" for injection of Isavuconazole approved and issued by the National Medical Products Administration. This drug is mainly used for the treatment of invasive aspergillosis and invasive mucormycosis in adults, with a total investment of approximately 7.12 million RMB as of the disclosure date of the announcement. 17 enterprises in China have already obtained the registration certificate for this drug. It is estimated that the sales revenue in the six major markets of China will be approximately 162 million RMB in 2024, and around 241 million RMB in the first three quarters of 2025. Obtaining the certificate will benefit the company by enriching its product line and accumulating experience in the development of generic drugs, but there is a risk that the drug sales may not meet expectations.